Comparative analysis of prospective study data of biochemical parameters of blood serum in patients with ischemic heart disease with the presence and absence of type 2 diabetes

Functional activity of the endothelium in groups of patients with ischemic heart disease and coronary heart disease in combination with diabetes under condition of absence of significant lesion of coronary arteries. Determine a set of laboratory parameters that determine the likelihood of developing cardiovascular complications. Materials. According to the data of selective coronary angiography, patients without significant coronary stenosis were identified. Group 1 - patients with IHD (n = 29), 2nd group - CHD with type 2 diabetes mellitus (DM), (n = 39). The study of laboratory parameters of blood serum was performed against the background of standard therapy before and after 12 ± 2.4 months of follow-up. Results. In both groups, the excess of the reference values of the parameters of the lipid profile and the markers of vascular inflammation was revealed. In the 2nd group the levels of total cholesterol, LDL, Apo-B, high-sensitivity C-reactive protein, homocysteine, interleukin 1 beta are significantly higher than in the 1st group. Prospective observation with standard therapy demonstrated the presence of negative dynamics of the lipid spectrum, the preservation of a prolonged response to the activation of the inflammatory reaction, which was indicated by interleukin 1 , homocysteine, matrix metalloproteinase 9 and the persistence of disorganization of the endothelin system in both groups of patients. Conclusion: The results of the study indicate the preservation of a prolonged inflammatory response in the endothelium in both the 1 st and 2 nd group of patients, which can become a provoking factor for the destabilization of the atherosclerotic process. The increased risk of atherothrombosis in both groups of patients requires a strict control of the effectiveness of the therapy in the conditions of real clinical practice.

ишемическая болезнь сердца, стабильная стенокардия, незначимый коронарный стеноз, сахарный диабет типа 2, липидный профиль, маркеры воспаления, coronary artery disease, type 2 diabetes mellitus, lipid profile, inflammatory markers, non-significant coronary artery stenosis

1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011-2030. Diabetes Res Clin Pract. 2011; 94(3):311-321.doi:10.1016/j.diabetes.2011.10.029

2. IDF atlas (7*edition update). Brussel, Belgium. International Diabetes Federation; 2015. available:http://www.diabetesatlas.org/

3. Hameed I, Massodi SR, Mir SA, et al.Type diabetesmellitus:Erom a metabolic disorder to an inflammatory condition. World J Diabetes.2015;6(4):598-612.doi:10.4239/wjd. v6.i4.598.

4. Kluppelholz B,Thorand B,Koenig W, et al. Association of subclinical inflammation with deterioration of glycaemia before the diagnosis of type 2 diabetes:the KORA S4 study. Diabetologia.2015;58(10):2269-2277. doi:10.1007/s00125-015-3679-4.

5. Grossmann V, Schmitt VH,Zeller T, et al. Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and type 2 Diabetes. Diabetes Care.2015;38(7):1356-1364.doi:10.2337/dc14-3008.

6. Kengne AP, Batty GD,Hamer M,et al.Assotiation of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 paticipants from four U.K. prospective cohort studies.Diabetes Care.2012;35(2):3960403.doi:102337/dc11-1588.

7. Petelina TI, Musikhina NA, Gapon LI, Kuznetsov VA, Gorbatenko LA, Ememva IV Specific parameters of lipid spectrum and markers of vascular inflammation in patients with stable angina and significant coronary artery stenosis with or without diabetes mellitus type 2. A prospective follow-up after angioplasty// Integrative Obesity and Diabetes, 2017. Volume 3(2): 1-8 doi: 10.15761/I0D.1000175.

8. Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, Stijnen T, Hofman A, Schram MT, Witteman JC. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007; 56(3):872-878.

9. Berezovskaya GA, Ganyukov VI, Karpenko MA. Restenosis and thrombosis within the stent: pathogenetic mechanisms of development. Russian Cardiology Journal 2012;6: 91-96.

10. Давыдчик Э.В., Снежитский В.А., Никонова Л.В. Взаимосвязь гипергомоцистеинемии с ишемической болезнью сердца и сахарным диабетом. Журнал Гродненского Государственного Медицинского Университета. 2015;1:9-

11. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. 2015; 18(1S):1-112

12. Безбородова Т.А., Тарасов А.А., Резникова Е.А., и др. Диагностическое использование новых патогенетических маркеров поражения сосудистой стенки у больных сахарным диабетом. Цитокины и воспаление. 2014;13(1):28-33

13. Джанашия П.Х., Мирина Е.Ю. Нарушение липидного обмена при сахарном диабете 2 типа и варианты его коррекции. //Русский медицинский журнал. -2008.-№11: статья 1561

14. Климонтов В.В., Тян Н.В., Фазуллина О.Н., и др. Клинические и метаболические факторы ассоциированные с хроническим воспалением низкой интенсивности у больных сахарным диабетом 2 типа.Сахарный диабет. 2016;(19)4:. 295-302

15. Гусев Д.Е., Потиевский Б.Г., Райчевин Н.А., и др. Маркеры воспаления при различных формах ишемической болезни сердца. Кардиология.- 2012.- №4 - С.4-8

16. Груздева О.В., Барбараш О.Л., Акбашева О.Е. Маркеры инсулинорезистентности и воспаления при инфаркте миокарда. «Цитокины и воспаление». 2012;(2):44-50

17. Бондарь И.А., Климонтов В.В.Система CD40-лиганд CD40 в развитии сахарного диабета и его осложнений. Сахарный диабет.2011;(3):21-26